08:15 - 08:30 Registration & welcome coffee
08:30 - 10:45 Workshop A - Interaction of screening, data analysis, library design and medicinal chemistryDr. Mark Hixon - Senior Fellow, Modeling & Simulation, Takeda Pharmaceuticals, USA
Overview about Screening Technologies
Screening Data Analysis
Library concepts of own synthesized compounds
Dr. Mark HixonSenior Fellow, Modeling & Simulation
Takeda Pharmaceuticals, USA
10:45 - 12:45 Workshop B - Prioritization of biophysical methods relative to the drug target and its mechanism of modulationDr. Pawel Stanczak - Scientist, Dart Neuroscience, USA
This interactive experience-based workshop will address the following approaches:
Prioritization of biophysical techniques to increase the success rate and speed up the FBDD process.
Discussion on PPI targets and prioritization of biophysical screenings for PPI targets. Selection of "intelligently designed" fragment libraries for those classes of targets.
Discussion on membrane proteins targets (mostly GPCRs) and prioritization of biophysical screenings for GPCRs.
Discussion on alternatives in FBDD (lack of crystal structures, low hit rate, etc.) using NMR spectroscopy and other biophysical tools.
Dr. Pawel StanczakScientist
Dart Neuroscience, USA
12:45 - 13:45 Networking luncheon
13:45 - 16:00 Workshop C - Intelligent library design and synthesis in practice: Strategies to build a screening collectionDr. Robert Goodnow - Executive Director, Chemistry Innovation Center, AstraZeneca, USA
This is a practical workshop following the optimized workflow towards the design and synthesis of the desired compound libraries.
Design of the screening collection
Diversity and targeted libraries
Exploration of alternate screening modalities
Analysis of screening results
Dr. Robert GoodnowExecutive Director
Chemistry Innovation Center, AstraZeneca, USA